STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANGO
  4. [Form 4] ANGIODYNAMICS INC Insider Trading Activity

AngioDynamics Inc. (ANGO) SVP receives 8,047 shares, 4,506 withheld for tax

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AngioDynamics Inc. executive Laura Piccinini, SVP International, reported vesting of performance share units granted on July 19, 2023. A target grant of 28,336 units resulted in 8,047 common shares being issued, while 4,506 shares were withheld at $13.82 per share for taxes and the remaining units were forfeited.

Positive

  • None.

Negative

  • None.
Insider Piccinini Laura
Role SVP International
Type Security Shares Price Value
Exercise Performance Right F3 28,336 $0.00 $0.00
Exercise Common Stock F1 8,047 $0.00 $0.00
Tax Withholding Common Stock F2 4,506 $13.82 $62K
Holdings After Transaction: Performance Right — 0 shares (Direct); Common Stock — 81,929 shares (Direct)
Footnotes (3)
  1. F1. This acquisition of 8,047 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
  2. F2. The exempt disposition of 4,506 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
  3. F3. On July 19, 2023, the reporting person received a target grant of 28,336 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,047 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
Performance share units target grant 28,336 units Target number of performance share units granted on July 19, 2023
Common shares issued from PSUs 8,047 shares Shares of Common Stock issued upon vesting and settlement of performance share units
Shares withheld for taxes 4,506 shares Common shares withheld as an exempt disposition to satisfy tax withholding obligations
Tax withholding price $13.82 per share Per-share value used for shares withheld to cover tax liabilities
Performance multiplier range 0% to 200% Range of units earnable versus target based on performance metrics
TSR-based adjustment portion 20% Portion of total shares earned subject to total shareholder return adjustment
Performance measurement fiscal years 2024, 2025, 2026 Fiscal years used to assess performance for the share unit award
performance share units financial
"the reporting person received a target grant of 28,336 performance share units"
Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.
tax withholding obligations financial
"made to satisfy tax withholding obligations in connection with the pre-determined vesting"
exempt disposition regulatory
"The exempt disposition of 4,506 shares of Common Stock of AngioDynamics"
total shareholder return financial
"based on total shareholder return relative to a peer group of companies"
Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.
peer group of companies financial
"relative to a peer group of companies over a three-year performance period"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did AngioDynamics (ANGO) report for Laura Piccinini?
AngioDynamics reported that SVP International Laura Piccinini settled a performance share unit award granted on July 19, 2023. The settlement delivered 8,047 shares of Common Stock, with the balance of the original units forfeited based on the award’s performance conditions.

How many AngioDynamics (ANGO) shares did Laura Piccinini receive and how many were withheld for taxes?
Laura Piccinini received 8,047 shares of AngioDynamics Common Stock from a vested performance award. Of these, 4,506 shares were treated as an exempt disposition and withheld at $13.82 per share to satisfy tax withholding obligations tied to the vesting event.

What was the original performance share unit grant disclosed for AngioDynamics (ANGO) SVP Laura Piccinini?
On July 19, 2023, Laura Piccinini received a target grant of 28,336 performance share units. Between 0% and 200% of this target could be earned based on fiscal 2024–2026 performance metrics and a relative total shareholder return adjustment.

How were performance conditions structured for the AngioDynamics (ANGO) performance share units?
The award allowed 0%–200% of the 28,336 target units to be earned based on pre-determined metrics for fiscal 2024, 2025 and 2026. An additional 20% of total shares earned could be adjusted up or down based on relative total shareholder return versus a peer group.

Were the AngioDynamics (ANGO) transactions for Laura Piccinini under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox was not marked as affirmative, and no footnote describes a trading plan. The reported vesting, withholding and forfeiture reflect pre-determined terms of a performance share unit award rather than an automatic share-sale program.

Does Laura Piccinini retain any performance rights from this AngioDynamics (ANGO) grant?
For this specific grant, the reporting shows 28,336 performance share units settled, with 8,047 shares issued and the remaining units forfeited. The derivative position for these performance rights is reported at 0 units following the transaction, indicating this award cycle is complete.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Piccinini Laura
(Last)(First)(Middle)
14 PLAZA DRIVE
(Street)
LATHAM NEW YORK 12110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP International
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/22/2026M8,047(1)A$086,435D
Common Stock07/22/2026F4,506(2)D$13.8281,929D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Right(3)07/22/2026M28,336 (3) (3)Common Stock28,336$00D
Explanation of Responses:
1. This acquisition of 8,047 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
2. The exempt disposition of 4,506 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
3. On July 19, 2023, the reporting person received a target grant of 28,336 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,047 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
/s/ Lawrence T. Weiss, Attorney in Fact07/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR